• Molecular NameNetilmicin
  • Synonym1-N-Ethylsisomicin
  • Weight475.587
  • Drugbank_IDDB00955
  • ACS_NO56391-56-1
  • Show 3D model
  • LogP (experiment)-3.981
  • LogP (predicted, AB/LogP v2.0)-5.26
  • pkaN/A
  • LogD (pH=7, predicted)-10.74
  • Solubility (experiment)100 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.32
  • LogSw (predicted, AB/LogsW2.0)779.65
  • Sw (mg/ml) (predicted, ACD/Labs)928.33
  • No.of HBond Donors11
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds8
  • TPSA199.73
  • StatusFDA approved; US withdrawn
  • AdministrationInjection or infusion
  • PharmacologyA member of the aminoglycoside family of antibiotics. These antibiotics have the ability to kill a wide variety of bacteria.
  • Absorption_value0.0
  • Absorption (description)Rapidly and completely absorbed after IM administration, peak serum levels were achieved within 30-60 minutes. Aminoglycosides are poorly absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding10.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNo evidence of metabolic transformation, typically 80% is recoverable in the urine within 24 hours
  • Half life2.5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityNetilmicin has the potential to cause disturbances in balance and a hearing loss.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A